Newsroom

• Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of corporate growth

• Kainova champions scientific agility, bold ambition, and unity of purpose

Montreal, Canada; Strasbourg, France; Boston, USA: Kainova Therapeutics (“Kainova” or “the Company”), a catalyst for breakthrough treatments for patients in immuno-oncology and inflammation, today announced a transformative rebrand. The new name and brand reflect the Company’s clinical momentum, global focus, and readiness for the next chapter of strategic growth, anchored by a mature pipeline of G Protein-Coupled Receptor (GPCR)-modulating therapies.

The name “Kainova” combines “Kairos,” the opportune or decisive moment, and “Nova,” symbolizing innovation and renewal. It embodies the Company’s transformation and ambition, reflecting its drive to innovate, determination to deliver, and commitment to therapies that truly transform lives. Built on a strong scientific foundation, a proprietary discovery platform, an integrated development approach, and experienced leadership, the new brand underscores Kainova’s commitment to clinical excellence, value creation, and lasting impact.

“The rebrand is not a break from our scientific or strategic roots,” said Sean A. MacDonald, Chief Executive Officer of Kainova Therapeutics. “It is the clearer expression of who we are today and the impact we strive to deliver for patients. It highlights a continuation between our past successes and the growth path we envision for the future. Above all, Kainova Therapeutics embodies our belief that better is always possible.”

Leveraging decades of scientific and medical expertise and a proven track record of collaborations with pharma, Kainova is advancing innovative, clinically differentiated therapies designed to unlock the untapped potential of GPCRs. Kainova employs a fully integrated, forward-thinking approach to GPCR drug discovery and smart development, moving programs efficiently from concept to clinic and strengthening its position as a leader in the field. The Company’s leading programs include DT-7012, a Treg-depleting anti-CCR8 antibody with competitive properties in Phase I/II trials for solid tumors, DT-9046, a first-in-modality, pre-IND biased PAR2 antagonist in inflammation, and DT-9081, a Phase II-ready EP4 receptor antagonist for solid tumors.

With operations in North America, France, and Australia, and a growing clinical pipeline, Kainova is entering its next chapter, shaping the future of GPCR-modulating therapies, transforming lives, and expanding its global reach.

The Kainova leadership will be in San Francisco during the J.P. Morgan Healthcare Conference, January 12–15, 2026, and welcomes the opportunity to share how the Company is advancing its clinical pipeline of GPCR-modulating therapies to create a meaningful impact for patients.

###

Contact
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens
+44 (0) 203 882 9621
kainova@optimumcomms.com

For French-speaking media:
communication@kainovatx.com

• Internationally recognized clinical strategist with proven track record in translating innovation into clinical impact joins Domain to advance its GPCR-targeting pipeline

• Appointment comes at a pivotal moment, following the initiation of Phase I/II development of DT-7012, a Treg-depleting anti-CCR8 antibody candidate

Strasbourg, France – Montreal, Canada – Boston, United States: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announced the appointment of Jean-Marie Cuillerot, M.D., as Chief Medical Officer (CMO).

Based in Boston, Dr Cuillerot brings extensive pharmaceutical and biotech experience, with a proven track record in leading successful clinical development programs and regulatory strategy. Earlier in his career, Dr Cuillerot served as the medical lead at Bristol-Myers Squibb for the lifecycle management of ipilimumab, the first approved immune checkpoint inhibitor for cancer. In this role, he designed and led pivotal Phase II and III clinical trials across multiple indications and supported regulatory filings in the United States and Europe.

At EMD Serono, an affiliate of Merck Serono, Dr Cuillerot held senior leadership positions as Global Head of Clinical Development in Immuno-Oncology and later as Vice President of Clinical Immunotherapy/Immuno-Oncology. Notably, he directed the clinical development of avelumab from pre-IND through global submissions in record time, an achievement recognized with the prestigious Merck CEO Award.

More recently, Dr Cuillerot served as CMO at Acrivon Therapeutics, Dragonfly Therapeutics, and at Agenus, where his leadership has consistently accelerated the progression of innovative therapies from early clinical stages toward regulatory milestones.

Sean A. MacDonald, Chief Executive Officer of Domain Therapeutics, said: “I am delighted to welcome Jean-Marie to the team. A distinguished industry leader with extensive expertise in the biotechnology and pharmaceutical sector, and a proven track record of leading clinical teams and optimizing clinical strategies, he is ideally positioned to help advance our innovative pipeline toward clinical proof of efficacy, driving our corporate growth.”

Dr Jean-Marie Cuillerot, newly appointed Chief Medical Officer of Domain Therapeutics commented: “Domain’s deep expertise in GPCR biology provides a strong foundation for a truly unique and differentiated approach to addressing unmet medical needs. Supported by promising preclinical and clinical data, the company’s GPCR-targeting therapies have the potential to deliver transformative outcomes for patients and be a game changer in immune system modulation. I look forward to collaborating with this talented team to advance these candidates through clinical development and toward a successful market entry. Together, we will drive meaningful innovation that benefits patients and creates lasting value for all our stakeholders.”

Dr Cuillerot joins Domain at a strategically significant inflection point, as the company accelerates clinical progress and prepares for key development milestones. Among these, is the ongoing Phase I/II DOMISOL trial in Australia for DT-7012, a Treg-depleting anti-CCR8 monoclonal antibody. DT-7012 is Domain’s second clinical stage candidate which reflects the continued momentum across its GPCR-targeting pipeline. By leveraging Dr Cuillerot’s deep clinical expertise and seasoned leadership, he will guide the development of DT-7012 while helping shape the strategic trajectory of Domain’s other proprietary and highly differentiated drug candidates, including DT-9081, an EP4 receptor antagonist for solid tumors, and DT-9046, a first-in-class biased negative allosteric modulator of PAR2 in inflammation. His insights will be instrumental in driving these programs toward value-creating milestones and supporting Domain’s next phase of growth.

###

Contact
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens
+44 (0) 203 882 9621
kainova@optimumcomms.com

For French-speaking media:
communication@kainovatx.com

• DT-7012 is a proprietary, differentiated Treg-depleting anti-CCR8 monoclonal antibody

• Differentiated binding capacities and competitive properties position it as a promising therapeutic to boost anti-tumor immunity, overcoming immunosuppression

Strasbourg, France – Montreal, Canada – Boston, United States: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announced that the first patients have been dosed in its Phase I / II DOMISOL clinical study of DT-7012, a differentiated Treg-depleting anti-CCR8 monoclonal antibody for the treatment of solid tumors.

The DOMISOL study is an open-label, multicenter Phase I / II, first-in-human dose-escalation and cohort-expansion trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of DT-7012 in adult patients with selected advanced solid tumors. The trial is being conducted in Australia, with initial clinical sites including Peninsula and Southeast Oncology ( PASO ) and Cabrini Health in Melbourne. Additional centers are expected to come online in the coming months. For more information on the trial, visit: NCT06819735.

Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: “CCR8 has rapidly emerged as a highly competitive target, drawing significant interest across the industry, including from leading pharmaceutical companies. DT-7012 stands out with its unique and differentiating properties, offering unprecedented selectivity in depleting intratumoral Tregs while simultaneously improving overall immune system function. These features are critical for effective cancer immunotherapy, positioning DT-7012 as a promising candidate to overcome immune resistance and bring hope to patients with limited treatment options.”

Professor Vinod Ganju, Principal Investigator at PASO, commented: “Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet a significant unmet need remains as Tregs suppress immune response, driving resistance to ICIs and limiting their effectiveness. We are excited to participate in this important trial and offer patients access to a highly promising therapeutic candidate that could make Treg depletion a reality in cancer therapy."

“Dosing of the first patients in the DOMISOL trial represents a significant milestone, as DT-7012 becomes our second fully proprietary asset to enter the clinic, underscoring our proven ability to translate cutting-edge GPCR biology into high value differentiated products”, added Sean A. MacDonald, Chief Executive Officer of Domain Therapeutics. “Initiating this trial in Australia aligns with our strategy to accelerate clinical development and strengthens momentum behind our pipeline of drug candidates. As we continue to advance our programs and deliver value for stakeholders, we are proud to contribute to the introduction of a potentially groundbreaking therapeutic solution that could transform lives of cancer patients worldwide.”

###

Contact
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens
+44 (0) 203 882 9621
kainova@optimumcomms.com

For French-speaking media:
communication@kainovatx.com